(Q37968558)

26 August 2017

A decade of the human genome sequence--how does the medicinal chemist benefit? (English)

1 reference

26 August 2017

Andreas Brunschweiger

series ordinal

1

1 reference

PubMed ID

22170741

26 August 2017

Jonathan Hall

series ordinal

2

1 reference

PubMed ID

22170741

26 August 2017

language of work or name

1 reference

13 December 2011

1 reference

26 August 2017

1 reference

26 August 2017

7

1 reference

26 August 2017

2

1 reference

26 August 2017

194-203

1 reference

Initial sequencing and analysis of the human genome

26 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

The Sequence of the Human Genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

The impact of genomics on drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Trends in the exploitation of novel drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

The Pfam protein families database

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

The Pfam protein families database

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Chemogenomic approaches to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Selective optimization of side activities: another way for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

The TB structural genomics consortium: providing a structural foundation for drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Structural genomics-impact on biomedicine and drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Structural genomics and drug discovery: all in the family

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

The impact of structural genomics: expectations and outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Chemogenomic approaches to rational drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Chemogenomics: an emerging strategy for rapid target and drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Identification of G protein-coupled receptor genes from the human genome sequence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

A physicogenetic method to assign ligand-binding relationships between 7TM receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: a chemogenomics approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

From astemizole to a novel hit series of small-molecule somatostatin 5 receptor antagonists via GPCR affinity profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

The protein kinase complement of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Kinomics-structural biology and chemogenomics of kinase inhibitors and targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Insights for the development of specific kinase inhibitors by targeted structural genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

High-throughput kinase profiling as a platform for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Arylcarboxyamino-substituted diaryl ureas as potent and selective FLT3 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

The clinical development of FLT3 inhibitors in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Protein tyrosine phosphatases: from genes, to function, to disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Protein tyrosine phosphatases in the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

PTP1B as a drug target: recent developments in PTP1B inhibitor discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Impaired bone marrow microenvironment and immune function in T cell protein tyrosine phosphatase-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Targeting the PTPome in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Structural and evolutionary relationships among protein tyrosine phosphatase domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Large-scale structural analysis of the classical human protein tyrosine phosphatome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

In silico screening for PTPN22 inhibitors: active hits from an inactive phosphatase conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Small molecule receptor protein tyrosine phosphatase γ (RPTPγ) ligands that inhibit phosphatase activity via perturbation of the tryptophan-proline-aspartate (WPD) loop

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

PARP inhibitors in cancer therapy: promise, progress, and puzzles

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

cDNA sequence, protein structure, and chromosomal location of the human gene for poly(ADP-ribose) polymerase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Toward a unified nomenclature for mammalian ADP-ribosyltransferases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Zinc binding catalytic domain of human tankyrase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Structural basis for the interaction between tankyrase-2 and a potent Wnt-signaling inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

JmjC-domain-containing proteins and histone demethylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Erasing the methyl mark: histone demethylases at the center of cellular differentiation and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Histone demethylation by hydroxylation: chemistry in action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Histone demethylation mediated by the nuclear amine oxidase homolog LSD1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Histone demethylation by a family of JmjC domain-containing proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Crystal structures of histone demethylase JMJD2A reveal basis for substrate specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Inhibitor scaffolds for 2-oxoglutarate-dependent histone lysine demethylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Selective Inhibitors of the JMJD2 Histone Demethylases: Combined Nondenaturing Mass Spectrometric Screening and Crystallographic Approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Isolation and characterization of cDNAs corresponding to an additional member of the human histone deacetylase gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Three proteins define a class of human histone deacetylases related to yeast Hda1p

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Cloning and characterization of a novel human histone deacetylase, HDAC8

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Cloning and characterization of a histone deacetylase, HDAC9

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Isolation and characterization of mammalian HDAC10, a novel histone deacetylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

A work in progress: the clinical development of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Isoform-specific histone deacetylase inhibitors: the next step?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Novel structural insights into class I and II histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Human HDAC7 Harbors a Class IIa Histone Deacetylase-specific Zinc Binding Motif and Cryptic Deacetylase Activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Will the ubiquitin system furnish as many drug targets as protein kinases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Drug discovery in the ubiquitin-proteasome system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

The therapeutic potential of deubiquitinating enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Novel approach for characterizing ubiquitin E3 ligase function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Characterization of ubiquitin and ubiquitin-like-protein isopeptidase activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Membrane transporters in drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Stearoyl-coenzyme A desaturase 1 inhibition and the metabolic syndrome: considerations for future drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

Synthesis and biological activity of a potent and orally bioavailable SCD inhibitor (MF-438).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1–induced Charcot-Marie-Tooth disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

21 January 2018

The human genome at ten

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

The impact of genomics on drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

7 January 2021

Genomics drugs in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

7 January 2021

A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

7 January 2021

Novel selective orally active CRTH2 antagonists for allergic inflammation developed from in silico derived hits

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

7 January 2021

Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

7 January 2021

Pfizer's JAK inhibitor sails through phase 3 in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1002%2FCMDC.201100498

7 January 2021

Identifiers

DOI

10.1002/CMDC.201100498

1 reference

26 August 2017

1 reference

PubMed ID

22170741